View Post

CytoDyn Treats First Patient in Phase 1b/2 Clinical Trial with Leronlimab (PRO 140) for Patients with Treatment-Naïve, Metastatic Triple-Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

From: globenewswire.com CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications announced today the injection of the first patient in a Phase 1b/2 clinical protocol with treatment-naïve metastatic triple-negative breast cancer (mTNBC). The treatment of the first patient in mTNBC with leronlimab …

View Post

G1 Therapeutics Announces Updated Results from Phase 2 Trial of Trilaciclib in Combination with Chemotherapy

In Clinical Trials by Barbara Jacoby

Source: G1 Therapeutics From: globenewswire.com G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced preliminary overall survival (OS) results from a randomized Phase 2 trial which demonstrated that women with metastatic triple-negative breast cancer (mTNBC) lived significantly longer when receiving trilaciclib and chemotherapy compared with women receiving chemotherapy alone. Detailed data from this trial will be presented at …